<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04725357</url>
  </required_header>
  <id_info>
    <org_study_id>JHOR20D.1216</org_study_id>
    <nct_id>NCT04725357</nct_id>
  </id_info>
  <brief_title>Does Meloxicam Provide as Much Pain Relief as Opioids After Shoulder Surgery?</brief_title>
  <official_title>A Randomized Comparison of Meloxicam to Opioids Following Arthroscopic Labrum Repairs of the Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The opioid epidemic continues to be a major concern, with orthopedic surgeons being among the&#xD;
      top prescribers of opioids. Studies evaluating these practices found that opioids are&#xD;
      overprescribed, even for common procedures. Patients undergoing arthroscopic labrum repair of&#xD;
      the shoulder were found to have an average of 20 pills left over after surgery. Many&#xD;
      strategies have been developed to tackle overprescribing and have found success, including no&#xD;
      opioid protocols for carpal tunnel release. The purpose of this study is to examine if&#xD;
      meloxicam alone provides similar patient reported outcomes to opioids following arthroscopic&#xD;
      labrum repair of the shoulder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">January 25, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Analgesic use</measure>
    <time_frame>14 days</time_frame>
    <description>Participants will be given a survey asking about number of pills taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain Control</measure>
    <time_frame>14 days</time_frame>
    <description>Measured by the Numerical Rating Scale (NRS) pain score daily after surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Shoulder Pain</condition>
  <arm_group>
    <arm_group_label>Arthroscopic Labral Repair + postoperative Meloxicam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After surgery participants will receive a prescription of 20 pills of 15 mg Meloxicam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arthroscopic Labral Repair without Meloxicam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After surgery participants will receive a prescription of 20 pills of 5/300 mg vicodin (hydrocodone/acetaminophen)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam 15 mg</intervention_name>
    <description>Participants will receive a prescription of 20 pills of 15 mg Meloxicam after surgery</description>
    <arm_group_label>Arthroscopic Labral Repair + postoperative Meloxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preoperative Interscalene Nerve Block</intervention_name>
    <description>Preoperatively participants will standardly receive an interscalene nerve block</description>
    <arm_group_label>Arthroscopic Labral Repair + postoperative Meloxicam</arm_group_label>
    <arm_group_label>Arthroscopic Labral Repair without Meloxicam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>arthroscopic labral repair</intervention_name>
    <description>participant will have their standard surgical procedure done</description>
    <arm_group_label>Arthroscopic Labral Repair + postoperative Meloxicam</arm_group_label>
    <arm_group_label>Arthroscopic Labral Repair without Meloxicam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18&#xD;
&#xD;
          -  Scheduled for arthroscopic labrum repair of the shoulder&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of opioid, acetaminophen, NSAID or local anesthetic allergy or intolerance, or&#xD;
             contraindications to these medications.&#xD;
&#xD;
          -  Currently on long-term preoperative narcotics&#xD;
&#xD;
          -  Scheduled for revision arthroscopic repairs of the shoulder&#xD;
&#xD;
          -  Unable/unwilling to consent for enrollment&#xD;
&#xD;
          -  Unable to complete postoperative surveys&#xD;
&#xD;
          -  History of chronic pain syndromes (fibromyalgia, chronic diffuse MSK pain, etc)&#xD;
&#xD;
          -  Patients under the age of 18&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Scheduled for concurrent procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>January 22, 2021</last_update_submitted>
  <last_update_submitted_qc>January 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

